Exscientia Ltd

EXAI | $4.39 3.29% 3.19% 360K

(0.0% 1d) (-26.3% 1m) (-14.6% 1y) (0.0% 2d) (3.1% 3d) (0.5% 7d) (-18.12% volume)
Earnings Calendar:
Market Cap: $ 530,691,854
https://www.exscientia.ai
Sec Filling | Patents | 2021 employees

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Exscientia's pipeline of internal and partnered programmes demonstrates its ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka.

treatment ai-driven pharmatech pkc theta inhibitor

add to watch list Paper trade email alert is off

Press-releases

Exscientia Business and Financial Update for the Full Year 2023
Published: 2024-03-21 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -0.65% | O: 0.14% H: 0.24% C: 0.24%
EXAI | $4.39 3.29% 3.19% 360K

| -36.15% | O: -3.35% H: 0.0% C: -7.39%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -0.55% | O: 0.3% H: 0.0% C: 0.0%
business year update financial

Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K

| -35.4% | O: -0.88% H: 1.66% C: -1.04%
report year financial results

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K

| -25.76% | O: 1.02% H: 0.0% C: -1.68%
precision cancer study platform

Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
Published: 2023-12-05 (Crawled : 16:00) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K

| -29.13% | O: -0.32% H: 1.46% C: 0.49%
influenza grant

Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
Published: 2023-11-21 (Crawled : 19:00) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K

| -24.74% | O: 0.52% H: 0.26% C: -8.03%
conference

Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
Published: 2023-09-20 (Crawled : 09:00) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K

| -13.44% | O: 20.95% H: 0.0% C: -25.98%
drug merck germany collaboration

Exscientia Business Update for Second Quarter and First Half of 2023
Published: 2023-08-10 (Crawled : 12:00) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K

| -40.97% | O: 0.0% H: 0.73% C: -6.74%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -10.6% | O: 1.52% H: 1.05% C: 0.47%
business update

Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023
Published: 2023-08-03 (Crawled : 12:00) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K

| -47.61% | O: -2.63% H: 6.27% C: 3.32%
report financial results

Exscientia Initiates Prospective Observational Study in Ovarian Cancer
Published: 2023-07-18 (Crawled : 15:00) - biospace.com/
EXAI | $4.39 3.29% 3.19% 360K